TrialDiabetes2022

SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.

Schafer C Boeder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.